HA
CNST

HHLR Advisors’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

HHLR Advisors’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-246,883
Closed -$1.59M – 67
2019
Q3 		$1.59M Buy
+246,883
New +$2.06M 0.02% 59

Other funds holding CNST

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

HHLR Advisors's CNST Position: Q4 2019 in Review

HHLR Advisors sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q4 2019, closing a stake of 246,883 shares — an estimated $1.59M sold.

HHLR Advisors first reported a position in CNST in Q3 2019 and held it in 1 quarter. The position peaked at $1.59M in Q3 2019. 100 funds tracked by Wall St. Rank hold CNST as of Q4 2019.

  • HHLR Advisors reported no remaining Constellation Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • HHLR Advisors sold 246,883 Constellation Pharmaceuticals, Inc. shares in Q4 2019, an estimated $1.59M.
  • HHLR Advisors first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2019 and held it in 1 quarter.
  • HHLR Advisors's Constellation Pharmaceuticals, Inc. position peaked at $1.59M in Q3 2019.
  • 100 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q4 2019.

Based on HHLR Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.